Skip to main content

Breast Cancer

Online First
Symptom Management Overview, Breast Cancer, Targeted Therapies
HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer
Courtney Muche, PharmD; Matthew Mattila, PharmD, BCOP
Read More
Online First
Case Reports, Breast Cancer, Tyrosine Kinase Inhibitor, Targeted Therapies
Response to Alectinib in Refractory Breast Cancer With an EML4-ALK Rearrangement
Mikaila Eross, PharmD; Sarah Shockley, PharmD, BCOP; Danielle Roman, PharmD, BCOP; Sarah Miller, DO; Christie Hilton, DO
Read More
Online First
Case Reports, Adverse Events, Drug–Drug Interaction, Breast Cancer
Simvastatin-Induced Rhabdomyolysis Potentially Triggered by Palbociclib Inhibition of CYP3A4: A Case Report
Madeleine Hosick, PharmD; Karam Abi Karam, DO; Kaitlyn Korah, PharmD; Kyla Bidne, PharmD, BCOP; Diana Tamer, PharmD, BCOP
Read More
Online First
Case Reports, Breast Cancer, Chemotherapy
Highly Effective Treatment for Bone-Only Signet Ring Cell Breast Cancer With Ribociclib, Fulvestrant, and Denosumab: A Case Study
Marjorie Ford Nenadich, PharmD, BS; Michelle Faith Nenadich, BSN; Basel Shoua, MD
Read More
Original Research, Adverse Events, Breast Cancer, CDK4/6 Inhibitors, Oncology Pharmacy Programs/Protocols
Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib
Katelin Ivey, PharmD, BCPS; Tristan Maiers, PharmD, BCOP; Justine Maley, PharmD
Read More
Online First
Case Reports, Breast Cancer, Prostate Cancer
Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report
Bryan P. Fitzgerald, PharmD; Allison Magnuson, DO, MS; Chunkit Fung, MD
Read More
Online First
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Breast Cancer, CDK4/6 Inhibitors, Adverse Events
Evaluation of Pharmacist-Driven Approach to Monitoring for Neutropenia Related to CDK4/6 Inhibitors in Women With Advanced Breast Cancer
Jianne De Raya, PharmD, and Jessie Modlin, PharmD, BCOP
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Read More
Page 1 of 12
Results 1 - 10 of 114